Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pharmaceutical composition of fingolimod hydrochloride and curcumenol in preparation of anti-multiple myeloma drug

A technology of fingolimod hydrochloride and multiple myeloma, applied in the field of anticancer drugs, can solve the problems of unseen multiple myeloma, achieve great development prospects and potential application value, induce cell necrosis, and inhibit cell proliferation Effect

Active Publication Date: 2020-08-07
CENT SOUTH UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] There is no report on the combined application of Fingolimod (FTY720) HCl and Curcumol in the research of multiple myeloma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pharmaceutical composition of fingolimod hydrochloride and curcumenol in preparation of anti-multiple myeloma drug
  • Application of pharmaceutical composition of fingolimod hydrochloride and curcumenol in preparation of anti-multiple myeloma drug
  • Application of pharmaceutical composition of fingolimod hydrochloride and curcumenol in preparation of anti-multiple myeloma drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] CCK-8 method was used to detect the effects of Fingolimod (FTY720) HCl and Curcumol on the survival rate of MM1S cells alone and in combination.

[0029] Experimental steps:

[0030] (1) Collect MM1S cells in the logarithmic growth phase (purchased from ATCC cell bank, USA), adjust the concentration of the cell suspension, add 100 μL to each well, and plate on a 96-well plate so that the cell density to be tested is 1×10 4 a / mL;

[0031] (2) A zero-adjustment group without adding cells and only culture medium and a DMSO control group with a volume concentration of 0.1% without adding drugs are set, and 3 parallel wells are set for each concentration;

[0032] (3) Add 3 μM Fingolimod (FTY720) HCl, 50 μg / mL Curcumol and 3 μM Fingolimod (FTY720) HCl and 50 μg / mL Curcumol joint preparation respectively, and place in 5% CO by volume 2 , incubate in a cell culture incubator at 37°C for 48 hours;

[0033] (4) Add 10 μL of CCK-8 solution to each well, incubate at 37°C in the...

Embodiment 2

[0036] The synergistic effect of different concentrations of Fingolimod (FTY720) HCl and Curcumol drug combination on MM1S cells was detected by CCK-8 method.

[0037] Experimental steps:

[0038] (1) Collect MM1S cells in the logarithmic growth phase, adjust the concentration of the cell suspension, add 100 μL to each well, and plate on a 96-well plate so that the cell density to be tested is 1×10 4 piece / m L;

[0039] (2) A zero-adjustment group without adding cells and only culture medium and a DMSO control group with a volume concentration of 0.1% without adding drugs are set, and 3 parallel wells are set for each concentration;

[0040] (3) Add different concentrations of Fingolimod (FTY720) HCl and Curcumol preparations, the concentrations of the joint preparations are 2μM+25μg / mL, 2μM+50μg / mL, 2μM+100μg / mL, 3μM+25μg / mL, 3μM+50μg / mL, 3μM+100μg / mL, 4μM+25μg / mL, 4μM+50μg / mL, 4μM+100μg / mL, placed in 5% CO2 by volume, 37°C cell culture incubator for 48 hours;

[0041] (4...

Embodiment 3

[0046] Annexin V 647 / PI method was used to detect the effects of Fingolimod (FTY720) HCl and Curcumol on the apoptosis of MM1S cells alone and in combination.

[0047] Experimental steps:

[0048] (1) Collect the MM1S cells in the logarithmic growth phase, and adjust the concentration of the cell suspension to 2.5×10 5 Each / mL in a 6-well plate, the total volume is 2mL, then add 3μM Fingolimod (FTY720) HCl, 50ug / mL Curcumol, and the combined preparation of 3μM Fingolimod (FTY720) HCl and 50ug / mL Curcumol, and the volume of no drug The DMSO treatment group with a concentration of 0.1% was used as a control, which was placed in a cell culture box and incubated for 27 hours;

[0049] (2) Collect the cells, centrifuge at 2500rpm, 4°C for 5min to collect the cells, wash the cells twice with pre-cooled DPBS, each time at 2500rpm, centrifuge at 4°C for 5min, collect 2-3×10 5 cells;

[0050] (3) Add 100 μL 1×Binding Buffer (Vazyme, Nanjing, China) to resuspend the cells;

[0051] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of a pharmaceutical composition of fingolimod hydrochloride and curcumenol in preparation of a medicine for an anti-multiple myeloma drug. According to the preparation method, the synergistic effect of Fingolimod (FTY720) HCl and Curcumol is utilized, compared with single use of the two medicines, the pharmaceutical composition has a better effect of inhibiting cell proliferation, remarkably induces cell necrosis, generates a stronger biological function, and greatly improves the efficiency of killing multiple myeloma cells MM1S. The pharmaceutical composition disclosed by the invention has a remarkable effect in a laboratory, is suitable for clinically treating multiple myeloma patients, and has a great development prospect and a potential application value.

Description

technical field [0001] The invention relates to a new application of a pharmaceutical composition, in particular to the application of a pharmaceutical composition of fingolimod hydrochloride and curcumol in the preparation of anti-multiple myeloma drugs. It belongs to the technical field of anticancer drugs. Background technique [0002] Multiple myeloma (multiple myeloma, MM) is a malignant proliferation of plasma cells, also known as myeloma, plasma cell myeloma or Kahler's disease. Its tumor cells originate from plasma cells in the bone marrow, which are cells in the final functional stage of B lymphocyte development. Therefore, multiple myeloma can be classified as B lymphocyte lymphoma. Abnormalities occur during the differentiation of B cells into plasma cells, resulting in the production of a large number of monoclonal immunoglobulin chains or light chains (M protein), which inhibits the proliferation of normal polyclonal plasma cells and the secretion of polyclona...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/137A61P35/00
CPCA61K31/137A61K31/352A61P35/00A61K2300/00
Inventor 孙曙明袁依俊赵铭日薛艳史国靓刘静
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com